bevacizumab-bvzr Zirabev
Selected indexed studies
- Ocular Safety and Toxicokinetics of Bevacizumab-bvzr (Zirabev), a Bevacizumab Biosimilar, Administered to Cynomolgus Monkeys by Intravitreal Injection. (J Ocul Pharmacol Ther, 2023) [PMID:36880872]
- Physicochemical stability of PF-06439535 (bevacizumab-bvzr; Zirabev(®)), a bevacizumab biosimilar, under extended in-use conditions. (J Oncol Pharm Pract, 2023) [PMID:35312402]
- Real-world usage of bevacizumab-bvzr biosimilar in US oncology practice. (Am J Manag Care, 2022) [PMID:35420744]
_Worker-drafted node — pending editorial review._
Connections
No connections recorded yet.
Sources
- Ocular Safety and Toxicokinetics of Bevacizumab-bvzr (Zirabev), a Bevacizumab Biosimilar, Administered to Cynomolgus Monkeys by Intravitreal Injection. (2023) pubmed
- Physicochemical stability of PF-06439535 (bevacizumab-bvzr; Zirabev(®)), a bevacizumab biosimilar, under extended in-use conditions. (2023) pubmed
- Real-world usage of bevacizumab-bvzr biosimilar in US oncology practice. (2022) pubmed
- Development of the Drug Product Formulation of the Bevacizumab Biosimilar PF-06439535 (Bevacizumab-bvzr). (2023) pubmed
- Does Biosimilar Bevacizumab Offer Affordable Treatment Options for Cancer Patients in the USA? A Budget Impact Analysis from US Commercial and Medicare Payer Perspectives. (2021) pubmed
- Unveiling the effects of light exposure Bevacizumab stability in clinical settings. (2026) pubmed
- Interventions to reduce waste and improve billing compliance with medications in single-dose vials. (2023) pubmed
- Safety of marketed biosimilar monoclonal antibody cancer treatments in the US: a disproportionality analysis using the food and drug administration adverse event reporting system (FAERS) database. (2025) pubmed
- Primary clear cell carcinoma of the vulva: A case report. (2023) pubmed
- Initial Experience With Biosimilar Bevacizumab-bvzr For Intravitreal Use in Children: A Case Series and Literature Review. (2023) pubmed